OrthoPediatrics (NASDAQ:KIDS) Rating Increased to Hold at Wall Street Zen

OrthoPediatrics (NASDAQ:KIDS) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other equities analysts have also recently issued research reports about the company. Truist Financial set a $18.00 price target on OrthoPediatrics in a report on Friday, October 10th. Stifel Nicolaus cut their target price on OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, October 10th. Piper Sandler reduced their target price on OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Citigroup reissued an “outperform” rating on shares of OrthoPediatrics in a report on Friday, October 10th. Finally, Needham & Company LLC dropped their price objective on shares of OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating for the company in a research note on Wednesday, October 29th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

OrthoPediatrics Price Performance

Shares of OrthoPediatrics stock opened at $18.41 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.40 and a quick ratio of 3.52. The company has a market cap of $461.72 million, a PE ratio of -9.44 and a beta of 1.06. The firm has a fifty day moving average price of $17.49 and a two-hundred day moving average price of $19.66. OrthoPediatrics has a fifty-two week low of $15.28 and a fifty-two week high of $27.60.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Monday, January 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. OrthoPediatrics had a negative return on equity of 6.86% and a negative net margin of 20.06%.The company had revenue of $25.08 million for the quarter. Analysts expect that OrthoPediatrics will post -0.93 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. grew its holdings in shares of OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares during the last quarter. Caption Management LLC acquired a new position in OrthoPediatrics in the third quarter valued at about $54,000. BNP Paribas Financial Markets boosted its position in OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after buying an additional 1,235 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in OrthoPediatrics during the second quarter worth about $220,000. Finally, PDT Partners LLC acquired a new stake in shares of OrthoPediatrics during the first quarter worth approximately $244,000. 69.05% of the stock is owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.